InSilico Medicine Cayman TopCo 3696

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

AI is accelerating drug screening, precision therapies and clinical trials, driven by cloud computing, rising R&D costs and demand for complex-disease treatments.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "AI in Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for AI in Drug Discovery was estimated at US$2.4 Billion in 2025 and is projected to reach US$14.3 Billion by 2032, growing at a CAGR of 28.8% from 2025 to 2032. This

Insilico Medicine Cayman TopCo (SEHK:3696) advanced its AI-discovered drug rentosertib into Phase III trials for idiopathic pulmonary fibrosis in China. The company reported that rentosertib is the first drug fully discovered and designed by its AI platform to reach Phase III testing. New research from Insilico Medicine indicated rentosertib may help reverse biological age markers in treated patients with fibrosis. The move of rentosertib into Phase III and its reported impact on biological...